Admin
Pagină nouă: <p>U.S. Food and Drug Administration (FDA) [https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-issues-complete-response-0 a refuzat] sa avizeze medicamentul propus de Eli Lilly contra bolii Alzheimer, denumit donanemab, indicand ca are nevoie de date suplimentare din teste clinice.</p><p>Decizia va intarzia cu cel putin cateva luni lansarea comerciala a noului medicament. Potrivit unei estimari FactSet [https://www.wsj.com/articles/n...